Clinical Trial Update: Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab-based therapy in previously treated high-grade malignant neuroendocrine carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High Grade Malignant Neuroendocrine Carcinoma

Drugs mentioned

• Pembrolizumab-based therapy (pembrolizumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) | Phase 2 | Status: COMPLETED | Results posted: 2022-12-27